Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

Jacobs Solutions CEO Bob Pragada joins 'Squawk Box' to discuss the building opportunities of life science facilities to meet ...

The GLP-1 medication trend has taken the health and wellness world by storm, largely hailed as a game-changer for weight loss ...

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

A retrospective study demonstrated that GLP-1 receptor agonist use before pregnancy corresponded with lower risks for ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.